News

April 11, 2022

BOSTON, April 11, 2022 -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy subjects in a phase 1 single ascending dose study. APNmAb005 is a unique antibody that recognizes a ...

December 28, 2021

APRINOIA Therapeutics has completed Series C financing with a total amount of $40 million USD in 2021. The financing was led by Yantai Dongcheng Pharmaceutical Group and syndicated by current shareholders KTB Network, IMM, and TaiAn Technologies and several new investors, including Harvest Capital, a fund established by the Management Committee of Suzhou Industrial Park (SIP). The new fun...

December 30, 2020

TAIPEI, Taiwan, Dec. 30, 2020 /PRNewswire/ --  Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative ...

December 16, 2020

APRINOIA Therapeutics Inc. today announced that they had executed a worldwide non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, for neurodegenerative diseases. This is an extension of a collaboration between APRINOIA and Biogen to discover novel PET imaging tracers for visualization and quantifi...

October 28, 2020

Suzhou, China- October 28, 2020- APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, targeting abnormal tau protein aggregates in brains of patients of cognitive impairment. 18F-APN-1607 is a new generation tau PET ...

November 21, 2019

APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational study of    F-APN-1607 in the US for its lead tau positron emission tomography (PET) tracer in Alzheimer's Disease (AD). The study (NCT number: NCT04141150) will compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns ...

August 30, 2019
APRINOIA Therapeutics has Initiated a Collaboration with Keio University in Tokyo, Japan
APRINOIA Therapeutics has initiated a collaboration with Keio University in Tokyo, Japan to profile patients with dementia using APRINOIA’s tau PET imaging tracer, 18F-APN-1607 (PM-PBB3). The collaboration is a part of the EKID (Eisai-Keio Innovation Laboratory for Dementia) study conducted by Keio University and Eisai Co. Ltd., which is supported by a research grant (No. JP17pc0101006) from AMED (Japan Agency for Medical Research and Development). APRINOIA is grateful for the opportunity to contribute to the study which might be useful for deeper understanding of dementia, especially Alzheimer’s Disease.
May 23, 2019

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers. ​APRINOIA has established a proprietary small molecule platfo...

March 26, 2019

Dr. Liang-Gee Chen, Minister of Ministry of Science and Technology (MOST), announced the 10 coolest tech startup companies today at Taiwan Tech Arena (TTA). The Taiwan government has invested the resources in building a tech startup ecosystem in Taiwan, this policy has encouraged many startups come up with innovative ideas and solution to emerged into the market. This year, the Ministry of Scie...